A method of treating prostate cancer in a subject with biochemically recurrent prostate cancer is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes phenelzine.

A method of treating prostate cancer in a subject with biochemically recurrent prostate cancer is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes phenelzine.

The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.

The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.

The present disclosure relates to prostate specific membrane antigen (PSMA) targeted compounds conjugated to near-infra red (NIR) dyes and methods for a method for synthesizing a compound of the formula:

##STR00001##

The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:

##STR00001##

The present disclosure describes compounds of Formula (I) and pharmaceutically acceptable salts thereof:

##STR00001##

Described herein are methods for preparing chiral ?-amino acids using chiral phosphoric acids as catalysts. The disclosed methods can use amino-malonic acids as substrates to generate chiral amino acids with a variety of side chains in high optional purity (such as an ee value of at least 70%) and with a high yield (i.e., a yield of at least 80%, such as in a range from about 80% to about 99%), via an asymmetric decarboxylation reaction. The decarboxylation reaction of the methods is catalyzed by chiral phosphoric acids that can achieve a selective protonation during decarboxylation, which is considered one of the most difficult processes in asymmetric catalysis.

Described herein are methods for preparing chiral ?-amino acids using chiral phosphoric acids as catalysts. The disclosed methods can use amino-malonic acids as substrates to generate chiral amino acids with a variety of side chains in high optional purity (such as an ee value of at least 70%) and with a high yield (i.e., a yield of at least 80%, such as in a range from about 80% to about 99%), via an asymmetric decarboxylation reaction. The decarboxylation reaction of the methods is catalyzed by chiral phosphoric acids that can achieve a selective protonation during decarboxylation, which is considered one of the most difficult processes in asymmetric catalysis.

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.